Cargando…

Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer

OBJECTIVE: Thyroid cancer (TC) is one of the fastest‐growing malignant tumors. This study sought to explore the mechanism of immune escape mediated by receptor tyrosine kinase (KIT) in TC. METHODS: The expression microarray of TC was acquired through the GEO database, and the difference analysis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Zhen, Xu, Jin, Xu, Dayong, Xu, Jiaojiao, Zhou, Rongjun, Deng, Keping, Chen, Zheng, Zou, Fang, Yao, Libo, Hu, Yuqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336654/ https://www.ncbi.nlm.nih.gov/pubmed/37506147 http://dx.doi.org/10.1002/iid3.851

Ejemplares similares

Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275/AXIN2 in natural killer cells
por: Ou, Zhenglin, et al.
Publicado: (2023)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

Role and significance of c-KIT receptor tyrosine kinase in cancer: A review
por: Sheikh, Emana, et al.
Publicado: (2022)

Correction to “Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations”
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Receptor tyrosine kinase C-kit promotes a destructive phenotype of FLS in osteoarthritis via intracellular EMT signaling
por: Cao, Xu, et al.
Publicado: (2023)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
por: D'allard, Diane, et al.
Publicado: (2013)

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

Does Generic Cyclic Kinase Insert Domain of Receptor Tyrosine Kinase KIT Clone Its Native Homologue?
por: Ledoux, Julie, et al.
Publicado: (2022)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1
Publicado: (1996)

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma
por: Eroukhmanoff, Juliette, et al.
Publicado: (2016)

The Role of Endosomal Escape and Mitogen-Activated Protein Kinases in Adenoviral Activation of the Innate Immune Response
por: Smith, Jeffrey S., et al.
Publicado: (2011)

Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
por: Malhotra, Anjli, et al.
Publicado: (2023)

Advances in research on immune escape mechanism of glioma
por: Guo, Xu, et al.
Publicado: (2023)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer
por: Nordgaard, Cathrine, et al.
Publicado: (2019)

Folding and Intrinsic Disorder of the Receptor Tyrosine Kinase KIT Insert Domain Seen by Conventional Molecular Dynamics Simulations
por: Ledoux, Julie, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

PDZ Binding Kinase/T-LAK Cell-Derived Protein Kinase Plays an Oncogenic Role and Promotes Immune Escape in Human Tumors
por: Feng, Tingting, et al.
Publicado: (2021)

The role of cancer-derived microRNAs in cancer immune escape
por: Yi, Ming, et al.
Publicado: (2020)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

The immune phenotypes and different immune escape mechanisms in colorectal cancer
por: Mao, Yihao, et al.
Publicado: (2022)

Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response
por: Guan, Di, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v84poq37lipvpc35131fltioha